Literature DB >> 3954128

Pharmacokinetics of fentanyl in patients undergoing abdominal aortic surgery.

R J Hudson, I R Thomson, J E Cannon, R M Friesen, R C Meatherall.   

Abstract

The authors determined the pharmacokinetics of fentanyl 100 micrograms X kg-1 iv in patients undergoing elective abdominal aortic surgery. The mean (+/- SD) age of the ten patients was 67.2 +/- 8.7 yr; their mean weight was 78.5 +/- 13.7 kg. Seven patients had aortic aneurysm repair, and the other three patients had aortobifemoral grafts. Serum fentanyl concentrations were determined from samples drawn at increasing intervals over a 24-h period. A three-compartment pharmacokinetic model was fit to the concentration versus time data. Total drug clearance was 9.8 +/- 1.8 ml X min-1 X kg-1. The volume of distribution at steady-state (Vdss) was 5.4 +/- 1.9 X 1 kg-1. Elimination half-time was 8.7 +/- 2.5 h. There were no significant correlations between these pharmacokinetic parameters and patient's age, duration of aortic cross-clamping, duration of surgery, intraoperative blood loss, or volume of iv fluids given intraoperatively. In healthy volunteers or patients undergoing general surgery, other investigators report mean elimination half-times for fentanyl ranging from 1.7 to 4.4 h. The prolonged elimination half-time in patients having abdominal aortic surgery has important clinical implications. In particular, recovery from large doses will take much longer than would have been anticipated from previously published fentanyl pharmacokinetic data.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3954128     DOI: 10.1097/00000542-198603000-00006

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  16 in total

Review 1.  Multiple peaking phenomena in pharmacokinetic disposition.

Authors:  Neal M Davies; Jody K Takemoto; Dion R Brocks; Jaime A Yáñez
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics.

Authors:  Mona Darwish; Mary Kirby; Philmore Robertson; Edward Hellriegel; John G Jiang
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers.

Authors:  Mona Darwish; Kenneth Tempero; Mary Kirby; Jeffrey Thompson
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  Pharmacokinetics of opioids in liver disease.

Authors:  I Tegeder; J Lötsch; G Geisslinger
Journal:  Clin Pharmacokinet       Date:  1999-07       Impact factor: 6.447

5.  Apnoea and unconsciousness after apparent recovery from alfentanil-supplemented anaesthesia.

Authors:  R J Hudson
Journal:  Can J Anaesth       Date:  1990-03       Impact factor: 5.063

Review 6.  Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.

Authors:  J Scholz; M Steinfath; M Schulz
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 7.  Anaesthesia for abdominal aortic surgery--a review (Part II).

Authors:  A J Cunningham
Journal:  Can J Anaesth       Date:  1989-09       Impact factor: 5.063

8.  Reduction and lumping of physiologically based pharmacokinetic models: prediction of the disposition of fentanyl and pethidine in humans by successively simplified models.

Authors:  Sven Björkman
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-08       Impact factor: 2.745

9.  Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study.

Authors:  Neha Parikh; Venkat Goskonda; Ashok Chavan; Larry Dillaha
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859

10.  Alfentanil pharmacokinetics in patients undergoing abdominal aortic surgery.

Authors:  R J Hudson; I R Thomson; P M Burgess; M Rosenbloom
Journal:  Can J Anaesth       Date:  1991-01       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.